دورية أكاديمية
أعرض في EDS

Evaluation of Fecal M2PK as a Diagnostic Marker in Colorectal Cancer.

التفاصيل البيبلوغرافية
العنوان: Evaluation of Fecal M2PK as a Diagnostic Marker in Colorectal Cancer.
المؤلفون: Dabbous HK; Tropical Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt., Mohamed YAE; Hepatogastroenterology and Tropical Medicine Department, Theodor Bilharz Research Institute, Cairo, Egypt., El-Folly RF; Tropical Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt., El-Talkawy MD; Hepatogastroenterology and Tropical Medicine Department, Theodor Bilharz Research Institute, Cairo, Egypt., Seddik HE; Hepatogastroenterology and Tropical Medicine Department, Theodor Bilharz Research Institute, Cairo, Egypt., Johar D; Department of Biochemistry and Nutrition, Faculty of Women for Arts, Sciences and Education, Ain Shams University, Cairo, Egypt. dinajohar@gmail.com.; Department of Physiology and Pathophysiology, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, 432 Basic Medical Sciences Building, 745 Bannatyne Avenue, Winnipeg, Manitoba, R3E 0J9, Canada. dinajohar@gmail.com., Sarhan MA; Center of Excellence of Gastrointestinal Inflammation and Immunology Research (CEGIIR), Gastroenterology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.; National Liver Institute, Department of Medical Microbiology and Immunology, Menofia University, Shibin El-Kom, Menofia, Egypt.
المصدر: Journal of gastrointestinal cancer [J Gastrointest Cancer] 2019 Sep; Vol. 50 (3), pp. 442-450.
نوع المنشور: Evaluation Study; Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer Science+Business Media Country of Publication: United States NLM ID: 101479627 Publication Model: Print Cited Medium: Internet ISSN: 1941-6636 (Electronic) NLM ISO Abbreviation: J Gastrointest Cancer Subsets: MEDLINE
أسماء مطبوعة: Publication: 2010- : New York : Springer Science+Business Media
Original Publication: New York, NY : Humana Press
مواضيع طبية MeSH: Adenomatous Polyps/*diagnosis , Biomarkers, Tumor/*metabolism , Colorectal Neoplasms/*diagnosis , Early Detection of Cancer/*methods , Feces/*enzymology , Pyruvate Kinase/*metabolism, Adenomatous Polyps/metabolism ; Adult ; Aged ; Case-Control Studies ; Colonoscopy ; Colorectal Neoplasms/metabolism ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Occult Blood ; Prognosis ; ROC Curve
مستخلص: Background: Invasive colonoscopy is the gold standard for patients at risk for colorectal cancer. However, the need for non-invasive and specific markers is required.
Objective: To evaluate the sensitivity of the glycolytic pyruvate kinase isoenzyme type M2 dimer (M2PK) as a diagnostic biomarker for colorectal cancer (CRC) and adenomatous colorectal polyps (CRP) screening.
Design: Case-control.
Patients: Twenty patients with CRC, 20 patients with CRP (lack criteria for colonic cancer by biopsy), and 20 normal subjects.
Outcome: Complete blood count (CBC), erythrocyte sedimentation rate (ESR), tumor markers: carcino embryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9), fecal occult blood test (FOBT), and fecal M2PK. Pelvic and abdominal ultrasound (US), colonoscopy, and a histopathological examination.
Results: Only weight loss and cachexia were significantly associated with CRC than CRP or control groups. M2PK was the most sensitive and specific test in differentiating CRC from CRP and the control subjects (sensitivity = 75%, specificity = 100%).
Limitations: (1) The selection of cases for three well-matched groups, as to perform colonoscopy in well-prepared cases and conditions. (2) Replicates in more than 20 cases for confirmation at the expense of enrolling new patients. (3) The cost associated with tumor markers analysis.
Conclusion: Fecal M2PK can be used as a precolonoscopy screening test for CRC patients, and is superior to other tumor markers, and in indicating the progress of colorectal adenomas > 1 cm. Thus being cost-effective and easy-to-perform test, it is a feasible tool to preselect patients who require colonoscopy.
References: Semin Oncol. 1999 Oct;26(5):556-60. (PMID: 10528904)
Minn Med. 1962 Apr;45:378-81. (PMID: 13860889)
N Engl J Med. 2004 Dec 23;351(26):2704-14. (PMID: 15616205)
Gastrointest Endosc Clin N Am. 2005 Jul;15(3):533-47, ix. (PMID: 15990056)
Am J Gastroenterol. 2006 Dec;101(12):2866-77. (PMID: 17227527)
CA Cancer J Clin. 2007 Mar-Apr;57(2):90-104. (PMID: 17392386)
Pancreas. 2007 Apr;34(3):318-24. (PMID: 17414054)
Colorectal Dis. 2008 Mar;10(3):244-8. (PMID: 17784868)
J Proteome Res. 2009 Mar;8(3):1368-79. (PMID: 19186948)
BMC Med. 2009 Apr 17;7:18. (PMID: 19374737)
Dtsch Med Wochenschr. 2010 Mar;135(12):557-62. (PMID: 20209426)
Int J Colorectal Dis. 2010 Oct;25(10):1177-84. (PMID: 20556397)
N Engl J Med. 2012 Feb 23;366(8):697-706. (PMID: 22356323)
World J Gastrointest Oncol. 2012 Jun 15;4(6):145-51. (PMID: 22737276)
World J Gastroenterol. 2012 Aug 14;18(30):4004-11. (PMID: 22912551)
Gastroenterology. 1990 Feb;98(2):371-9. (PMID: 2403953)
Gut Liver. 2015 Sep 23;9(5):641-8. (PMID: 25473070)
J Cancer Res Ther. 2014 Dec;10 Suppl:307-9. (PMID: 25693941)
PLoS One. 2015 Jul 09;10(7):e0131616. (PMID: 26158845)
J Gastrointestin Liver Dis. 2016 Mar;25(1):71-7. (PMID: 27014756)
Gastroenterology. 1982 May;82(5 Pt 1):891-8. (PMID: 7060910)
Gastrointest Endosc Clin N Am. 1996 Apr;6(2):343-77. (PMID: 8673332)
فهرسة مساهمة: Keywords: Colorectal cancer; Colorectal polyp; Egypt; Fecal occult blood test; Marker; Patients
المشرفين على المادة: 0 (Biomarkers, Tumor)
EC 2.7.1.40 (Pyruvate Kinase)
تواريخ الأحداث: Date Created: 20180408 Date Completed: 20200122 Latest Revision: 20200225
رمز التحديث: 20231215
DOI: 10.1007/s12029-018-0088-1
PMID: 29626277
قاعدة البيانات: MEDLINE
الوصف
تدمد:1941-6636
DOI:10.1007/s12029-018-0088-1